Key Takeaways Capacity expansion, backward integration, and biosimilar launches are set to drive margin improvement, free cash flow, and revenue growth well above consensus expectations. Strategic US localization and specialty segment expansion position Aurobindo for outsized gains in market share, pricing power, and long-term portfolio premiumization.Read more
Key Takeaways Rising compliance, environmental, and production costs threaten to erode margins and suppress earnings across Aurobindo Pharma's core businesses. Overexposure to mature markets and limited progress in complex generics expose the company to increased competition and persistent revenue risks.Read more
Key Takeaways Expansion into biosimilars, specialty products, and US acquisitions is strengthening Aurobindo's portfolio, market access, and earnings potential. Increased manufacturing capacity, in-house production, and investment in complex generics support margin expansion, efficiency, and long-term growth.Read more
Aurobindo Pharma Limited, a biopharmaceutical company, develops, manufactures, commercializes, and sells generic pharmaceuticals, active pharmaceutical ingredients (APIs), and injectables. The company offers formulation in form of oral solids, liquids, injectables, vaccines, and metered dose inhalers; and APIs, biosimilars, and peptides targeting therapeutic areas, such as central nervous system, cardiovascular, respiratory, antibiotics, anti-retroviral, anti-diabetics, gastroenterology, oncology, and dermatology. It also provides antiretroviral drugs for the people and children living with HIV; and API space for sterile and non-sterile penicillin’s, cephalosporins, penems, and non-beta lactams. The company has operations in India, the United States, Europe, Puerto Rico, and internationally. The company was incorporated in 1986 and is headquartered in Hyderabad, India.
